UPDATE: Jefferies Upgrades Medifast (MED) to Buy

Jefferies analyst Stephanie Wissink upgraded Medifast (NYSE: MED) from Hold to Buy with a price target of $265.00 (from $205.00).

The analyst comments "We are upgrading shares of MED to Buy as we see the company well positioned to grow its leading role in the wellness sector over the next 12-24 months. Rising consumer health centric attitudes, well depicted in our mid-Jan proprietary survey here, have driven interest in OPTAVIA to an all-time high setting the scene for a robust 2021. We are taking our est. above cons. and see risk biased to the upside. Our new $265 PT = ~22x '22 EPS."

For an analyst ratings summary and ratings history on Medifast click here. For more ratings news on Medifast click here.

Shares of Medifast closed at $220.87 yesterday.

You May Also Be Interested In

• Chr Hansen Holding A/S (CHR:DC) (CHYHY) PT Lowered to DKK610 at UBS
• Nomura/Instinet Upgrades Wipro Ltd. (WPRO:IN) (WIT) to Neutral
• ESR Cayman Ltd (1821:HK) (ESRCF) PT Raised to HK$29.20 at Morgan Stanley